Marks Baxter’s entry into the attractive global hemostatic powder segment, broadening its portfolio offering to include a wider range of active and passive solutions Addressing intraoperative bleeding ...

In the study of over 200 patients, 90.1% of those who received TC-325 had their bleeding controlled within 30 days, as compared to 81.4% of those who received standard treatment, meeting criteria for ...

Marks first passive hemostat for Baxter in the U.S. market, broadening portfolio offering to include a full range of active and passive hemostatic products PERCLOT further enhances clinicians’ ability ...

SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Nextbiomedical announced today that its novel hemostatic powder, Nexpowder™, has been published in GUT (Impact Factor: 23), one of the world's most ...

SOMERVILLE, N.J., June 6, 2017 /PRNewswire/ -- Uncontrolled bleeding during surgery can adversely affect patient outcomes, hospital costs and resources. 1-9 Primary methods of hemostasis alone may be ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--EndoClot Plus, Inc., a privately held medical device company founded by surgeons and biomaterial scientists announces the CE approval of EndoClot ® Adhesive ...

COLLEGE PARK, Md., Sept. 25, 2024 /PRNewswire/ -- Medcura, Inc., a leader in innovative hemostasis solutions that deploy patented biopolymer technologies to control surgical bleeding, is pleased to ...

It sounds like sci-fi, but it’s real. Scientists have discovered a revolutionary way to stop uncontrollable bleeding in just one second. See how it works.

Marks Baxter’s entry into the attractive global hemostatic powder segment, broadening its portfolio offering to include a wider range of active and passive solutions Indications: PerClot ...